Description: Nuvalent, Inc., a preclinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor, designed to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and also remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors; and NVL-655, a brain-penetrant ALK-selective inhibitor, designed to inhibit ALK fusions that express the normal ALK kinase domain without any drug-resistant mutations and also remain active in the presence of mutations conferring resistance to first, second, and third generation ALK inhibitors. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Home Page: www.nuvalent.com
NUVL Technical Analysis
One Broadway
Cambridge,
MA
02142
United States
Phone:
857 357 7000
Officers
| Name | Title |
|---|---|
| Dr. James R. Porter Ph.D. | CEO, Pres & Director |
| Prof. Matthew D. Shair Ph.D. | Founder, Head of Scientific Advisory Board & Director |
| Ms. Deborah Ann Miller J.D., Ph.D. | Chief Legal Officer & Sec. |
| Dr. Christopher D. Turner M.D. | Chief Medical Officer |
| Ms. Alex Balcom CPA, M.B.A. | CFO & Treasurer |
| Dr. Benjamin Lane | Sr. VP of Technical Operations |
| Mr. Matthew Metivier | VP of HR |
| Ms. Darlene Noci | Chief Devel. Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 7.398 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-07-29 |
| Fiscal Year End: | December |
| Full Time Employees: | 57 |